PHILADELPHIA – A Philadelphia jury awarded $ 8 billion in punitive damages to Johnson & Johnson and a subsidiary for a drug on Tuesday. According to the plaintiff's lawyers, these companies have linked up with the abnormal growth of female breast tissue in boys.  Johnson & Johnson denounced the award immediately after the jury's decision before the court on the grounds that it was "overblown and unfounded" and swore to take immediate action to lift it.
Risperdal antipsychotic is at the heart of the lawsuit The plaintiff's lawyers argue that this is related to abnormal growth of female breast tissue in boys, an incurable condition known as gynecomastia.
Johnson & Johnson used an organized system to make billions of dollars while attorneys Tom Kline illegally marketed and promoted the drug, and Jason Itkin said in a statement.
Kline and Itkin said that Johnson & Johnson was "a company that gained profits over safety and p rofits about patients." Thousands of lawsuits were filed for the drug, but the lawyers said this was the first time that a jury decided on the imposition of punitive damages and set an amount.
Johnson & Johnson stated in a statement on its website that this was a case of confidence that the arbitral award would be repealed, which described it as "grossly disproportionate" with the original damages and as "a clear breach of due process" Defense, including a drug label that "clearly and appropriately demonstrates the risks associated with the drug," or the benefits of Risperdal for patients with severe mental illness. They also said that the plaintiff's lawyers provided no evidence of actual damage.
"This decision is in conflict with several provisions outside of Philadelphia regarding the appropriateness of the Risperdal label, the efficacy of the drug, and findings in support of the company." Johnson & Johnson said. "We will immediately try to lift this exaggerated and unfounded verdict."
Last week, the pharmaceutical company and its subsidiary Janssen agreed on a $ 20.4 million settlement with two Ohio counties to avoid a lengthy and costly federal trial on the opioid addiction epidemic.
The Company agreed to pay a combined $ 1